Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy
| Autor: | Lambros Tselikas, Eric Angevin, Antoine Hollebecque, Jean-Yves Scoazec, Francesco Facchinetti, Aline Maillard, Maud Ngo-Camus, C. Naltet, Ken A. Olaussen, Anas Gazzah, Stefan Michiels, Fabrice Andre, Thierry de Baere, Ludovic Bigot, David Planchard, Gilles Vassal, Ludovic Lacroix, Eric Solary, Catherine Richon, Luc Friboulet, Olivier Deas, Benjamin Besse, Linda Mahjoubi, Claudio Nicotra, Rastislav Bahleda, Yohann Loriot, Rosa L. Frias, Pernelle Lavaud, Aurelie Abou Lovergne, Gonzalo Recondo, Laura Mezquita, Christophe Massard, Jean-Charles Soria, Alexander M.M. Eggermont |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Oncology Cancer Research medicine.medical_specialty medicine.medical_treatment lcsh:RC254-282 DNA sequencing Article 03 medical and health sciences 0302 clinical medicine Internal medicine Biopsy medicine Clinical endpoint Adverse effect Cancer genetics Exome sequencing Therapeutic strategy medicine.diagnostic_test business.industry Disease progression Immunotherapy lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens 3. Good health 030104 developmental biology 030220 oncology & carcinogenesis business Biomarkers |
| Zdroj: | NPJ Precision Oncology npj Precision Oncology npj Precision Oncology, Vol 4, Iss 1, Pp 1-8 (2020) |
| ISSN: | 2397-768X |
| Popis: | Unravelling the biological processes driving tumour resistance is necessary to support the development of innovative treatment strategies. We report the design and feasibility of the MATCH-R prospective trial led by Gustave Roussy with the primary objective of characterizing the molecular mechanisms of resistance to cancer treatments. The primary clinical endpoints consist of analyzing the type and frequency of molecular alterations in resistant tumours and compare these to samples prior to treatment. Patients experiencing disease progression after an initial partial response or stable disease for at least 24 weeks underwent a tumour biopsy guided by CT or ultrasound. Molecular profiling of tumours was performed using whole exome sequencing, RNA sequencing and panel sequencing. At data cut-off for feasibility analysis, out of 333 inclusions, tumour biopsies were obtained in 303 cases (91%). From these biopsies, 278 (83%) had sufficient quality for analysis by high-throughput next generation sequencing (NGS). All 278 samples underwent targeted NGS, 215 (70.9%) RNA sequencing and 222 (73.2%) whole exome sequencing. In total, 163 tumours were implanted in NOD scid gamma (NSG) or nude mice and 54 patient-derived xenograft (PDX) models were established, with a success rate of 33%. Adverse events secondary to invasive tumour sampling occurred in 24 patients (7.6%). Study recruitment is still ongoing. Systematic molecular profiling of tumours and the development of patient-derived models of acquired resistance to targeted agents and immunotherapy is feasible and can drive the selection of the next therapeutic strategy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|